Compare DRCT & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | HSCS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.5M |
| IPO Year | 2022 | 2022 |
| Metric | DRCT | HSCS |
|---|---|---|
| Price | $0.07 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 24.1M | 36.8K |
| Earning Date | 11-06-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,369,000.00 | $6,250.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $2.01 |
| 52 Week High | $6.59 | $6.47 |
| Indicator | DRCT | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 22.58 | 42.26 |
| Support Level | $0.09 | $2.55 |
| Resistance Level | $0.09 | $3.00 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 3.26 | 29.69 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.